AXL and neoplasm: Further targeted inactivation of AXL with a small molecule inhibitor BMS-777607 leads to a significant decrease of tumor cell growth in vitro and in vivo due to increased intratumoral apoptosis, impaired proliferation, invasion and neovascularization [7].